Postoperative Adjuvant TACE Treatment in CK18 Positive Patients

Eastern Hepatobiliary Surgery Hospital320 enrolled

Overview

To evaluate and analyse the clinical effect and application value of postoperative adjuvant TACE treatment in patients with different expression levels of CK18 using randomized controlled study and provide evidence for the necessity of postoperative adjuvant TACE.

Study Type

OBSERVATIONAL

Enrollment

320

Conditions

Postoperative Adjuvant TACE Hepatocellular Carcinoma.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Via clinical diagnosis and confirm it is primary liver cancer 2. Pathological evidence of HCC 3. Estimate tumor can gain treatment of curing operation 4. No evidence for extrahepatic metestasis 5. liver function ：Child-Pugh A/B Exclusion Criteria: 1. reject to attend； 2. impossible to come to our hospital for physical examination regularly. 3. cancer epitome、seed focus、lymph node or distant metastasis 4. Blood clotting function hindrance; 5, Patients with other diseases which may affect the treatment mentioned.

Locations (1)

Eastern hepatobilliary surgery hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Overall survival

Time frame: 3 years

Secondary Outcomes

Time to recurrence

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.